October 1, 2022 | Targeted Therapies in Oncology

The Role of Biomarker Testing in Ovarian Cancer

October 17, 2022

Clinical Articles

There is no single best treatment algorithm for ovarian cancer. Treatment decisions, which become increasingly complex with disease progression, are informed by several patient-specific clinicopathologic parameters and genomic results.

Greater Understanding of the Biology of NSCLC Propels Treatment Options Forward

October 17, 2022

Clinical Articles

Prior to the 20th Annual Winter Lung Cancer Conference, Mark A. Socinski, MD, spoke with Targeted Therapies in Oncology about expectations for the upcoming meeting and major topics in non–small cell lung cancer.

Regorafenib Then Nivolumab Sequence Is Tolerable After First-Line HCC Treatment

October 14, 2022

Clinical Articles

Data presented during the 2022 International Liver Cancer Association Conference showed that less than one-third of patients with hepatocellular carcinoma who received regorafenib followed by nivolumab experienced grade 3 or 4 treatment-related adverse events.

Gene Expression Signatures Are Analyzed for Biomarkers of Response in HCC

October 14, 2022

Clinical Articles

The phase 1b Study 116/KEYNOTE-524 trial of lenvatinib and pembrolizumab revealed the RAS gene signature to possibly be associated with progression-free survival in unresectable hepatocellular carcinoma.

Emerging Therapies in Breast Cancer Excite the Field

October 13, 2022

Clinical Articles

Despite advances in the treatment of breast cancer, challenges remain, such as the development of resistance to existing therapies, serious adverse events, and suboptimal treatment adherence.